Abstract
Traumatic brain injury is a major cause of morbidity and mortality worldwide. Currently, the only treatment is supportive, with an emphasis on prevention of secondary injury. Our lab has over a decade of experience investigating histone deacetylase inhibitors (HDACIs), mainly valproic acid (VPA), as a treatment to improve survival and recovery after traumatic brain injury. In this chapter, we will review the cellular changes that occur after traumatic brain injury, the promising results of preclinical use of VPA in TBI, and the future of VPA use in traumatic brain injury.
Original language | English (US) |
---|---|
Title of host publication | Diagnosis and Treatment of Traumatic Brain Injury |
Subtitle of host publication | The Neuroscience of Traumatic Brain Injury |
Publisher | Elsevier Inc |
Pages | 477-484 |
Number of pages | 8 |
ISBN (Electronic) | 9780128233474 |
ISBN (Print) | 9780128233481 |
DOIs | |
State | Published - Jan 1 2022 |
Keywords
- Acetylation
- Epigenetics
- Histone deacetylase inhibitor
- Neurodegeneration
- Neurologic outcomes
- Neuroplasticity
- Pro-survival
- Traumatic brain injury
- Valproic acid
ASJC Scopus subject areas
- General Medicine
- General Neuroscience